BDBM107703 US10889546, US2007/0299086 Table 2.4::US11426393, Compound Table XV.9::US8598210, Table XV, 9::US8722895, 9: {[5-(4-Chlorophenyl)-3-hydroxypyridine-2- carbonyl]amino}-acetic acid::US9598370, Example 00134::USRE47437, Example {[5-(4-Chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic acid

SMILES OC(=O)CNC(=O)c1ncc(cc1O)-c1ccc(Cl)cc1

InChI Key InChIKey=DLUPTLSWWQTJFJ-UHFFFAOYSA-N

Data  11 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 107703   

TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US10889546, US2007/0299086 Table 2.4 | US11426393,...)
Affinity DataIC50:  240nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US10889546, US2007/0299086 Table 2.4 | US11426393,...)
Affinity DataIC50:  83nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US10889546, US2007/0299086 Table 2.4 | US11426393,...)
Affinity DataIC50:  240nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US10889546, US2007/0299086 Table 2.4 | US11426393,...)
Affinity DataIC50:  83nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US10889546, US2007/0299086 Table 2.4 | US11426393,...)
Affinity DataIC50:  240nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US10889546, US2007/0299086 Table 2.4 | US11426393,...)
Affinity DataIC50:  83nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US10889546, US2007/0299086 Table 2.4 | US11426393,...)
Affinity DataIC50:  240nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US10889546, US2007/0299086 Table 2.4 | US11426393,...)
Affinity DataIC50:  83nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US10889546, US2007/0299086 Table 2.4 | US11426393,...)
Affinity DataIC50:  1.39E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALD...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US10889546, US2007/0299086 Table 2.4 | US11426393,...)
Affinity DataIC50:  240nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US10889546, US2007/0299086 Table 2.4 | US11426393,...)
Affinity DataIC50:  83nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent